Excerpt from Conflict of Interest, Protection of Public Ownership, in Drug Development Deals Between Tax-Exempt, Federally Supported Labs and the Pharmaceutical Industry, Vol. 2: Hearing Before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business House of Representatives One Hundred Third Congress First, Washington, DC, June 17, 1993 Conflict of Interest, Protection of Public Ownership, in Drug Development Deals Between Tax-Exempt, Federally Supported Labs and the Pharmaceutical Industry: Hearing Before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business House of Representatives One Hundred Third Congress First, Washington, DC, June 17, 1993 was written by an unknown author in 1993. This is a 165 page book, containing 56239 words and 9 pictures. Search Inside is enabled for this title. About the Publisher Forgotten Books publishes hundreds of thousands of rare and classic books. Find more at www.forgottenbooks.com This book is a reproduction of an important historical work. Forgotten Books uses state-of-the-art technology to digitally reconstruct the work, preserving the original format whilst repairing imperfections present in the aged copy. In rare cases, an imperfection in the original, such as a blemish or missing page, may be replicated in our edition. We do, however, repair the vast majority of imperfections successfully; any imperfections that remain are intentionally left to preserve the state of such historical works.

Excerpt from Conflict of Interest, Protection of Public Ownership, in Drug Development Deals Between Tax-Exempt, Federally Supported Labs and the Pharmaceutical Industry: Hearing Before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business House Representatives One Hundred Third Congress, First Session, Washington, DC, March 11, 1993 The subcommittee met, pursuant to notice, at 9:38 a.m., in room 2359-A, Rayburn House Office Building, Hon. Ron Wyden, (chairman of the subcommittee) presiding. Chairman Wyden. The subcommittee will come to order. Today, the Subcommittee on Regulation, Business Opportunities, and Technology continues its 2-year-long inquiry into the pricing of drugs and medical devices which is the result of cooperation between taxpayer-supported, nonprofit, research laboratories and the pharmaceutical industry. The potential importance to the Nation's public health of this medical research collaboration is not in dispute. From these projects flow life-enhancing treatments for cancer, medications for cardiovascular disease, and cures for diseases and conditions that formerly meant death or a lifetime of disability for many of our fellow citizens. But this collaboration over time also has cemented the economic foundation of a very large, very profitable industry. On a continuing and increasing basis, the pharmaceutical industry mines a mother lode of valuable medical discoveries from a laboratory system that Federal taxpayers support with almost $10 billion per year. Of this $10 billion, $3 dollars of every $4 go to a university or independent lab. The Federal administrators who supervise this system appear to have little control over the prices charged by private drug manufacturers, who are their partners in either project-specific or broad-based research ventures. This system results in the commercialization of drugs discovered and developed in Federal laboratories, then priced out of sight by the pharmaceutical industry. About the Publisher Forgotten Books publishes hundreds of thousands of rare and classic books. Find more at www.forgottenbooks.com This book is a reproduction of an important historical work. Forgotten Books uses state-of-the-art technology to digitally reconstruct the work, preserving the original format whilst repairing imperfections present in the aged copy. In rare cases, an imperfection in the original, such as a blemish or missing page, may be replicated in our edition. We do, however, repair the vast majority of imperfections successfully; any imperfections that remain are intentionally left to preserve the state of such historical works.

This work has been selected by scholars as being culturally important, and is part of the knowledge base of civilization as we know it. This work was reproduced from the original artifact, and remains as true to the original work as possible. Therefore, you will see the original copyright references, library stamps (as most of these works have been housed in our most important libraries around the world), and other notations in the work. This work is in the public domain in the United States of America, and possibly other nations. Within the United States, you may freely copy and distribute this work, as no entity (individual or corporate) has a copyright on the body of the work. As a reproduction of a historical artifact, this work may contain missing or blurred pages, poor pictures, errant marks, etc. Scholars believe, and we concur, that this work is important enough to be preserved, reproduced, and made generally available to the public. We appreciate your support of the preservation process, and thank you for being an important part of keeping this knowledge alive and relevant.